Core Viewpoint - The announcement details that Qingdao Jiushi Investment Management Co., Ltd. has increased its stake in Qingdao Haier Biomedical Co., Ltd. to 5% through market transactions, reflecting confidence in the company's future development and long-term investment value [2][4]. Group 1: Shareholding Changes - Jiushi Youxuan No. 1 Private Securities Investment Fund acquired 15,897,909 shares of Haier Biomedical, representing 5% of the total share capital, between August 14, 2024, and October 14, 2025 [4][14]. - The increase in shareholding does not trigger a mandatory tender offer [2][5]. - The change in shareholding will not alter the company's controlling shareholder or actual controller [3][5]. Group 2: Investment Rationale - The investment is based on the belief in the future prospects of the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [11]. - The funding for the share acquisition comes from Jiushi Youxuan's own capital [4][14]. Group 3: Future Plans - As of the report's signing date, there are no specific plans or agreements for further increasing or decreasing the stake in the next 12 months [13].

【导读】海尔生物被久实优选1号私募证券投资基金举牌 中国基金报记者 吴君 10月15日晚间，海尔生物发布公告称，在本次增持以后，青岛久实投资管理有限公司（以下简称久实投 资）旗下久实优选1号私募证券投资基金（以下简称久实优选1号）拥有权益的股份数量及占公司总股本 的比例为5%，达到举牌线。 值得注意的是，海尔生物股价已经连续调整4年左右。国资背景的久实投资此时出手举牌，公司表示意 在未来发展中实现协同共赢。 久实投资举牌海尔生物 海尔生物最新发布公告称，2025年10月15日，公司收到久实投资（代表"久实优选1号"）发来的《简式 权益变动报告书》，基于对公司未来发展前景的信心和对公司长期投资价值的认可，久实优选1号于 2024年8月14日至2025年10月14日通过二级市场集中竞价和大宗交易方式增持公司股份1589.79万股，占 公司总股本的5.00%。 | 基金名称 | 基金备案编号 | 久实优选1号私募证券投资基金 SJD567 | | | | | | --- | --- | --- | --- | --- | --- | --- | | 信息披露 义务人基 | | | | | | | | 基金管理人名称 ...

Core Viewpoint - Haier Biomedical has been targeted by Qindao Jiushi Investment Management Co., Ltd. through its private equity fund, Jiushi Preferred No. 1, which has acquired a 5% stake in the company, marking a significant investment after four years of stock price decline [2][4][12]. Group 1: Investment Details - Jiushi Preferred No. 1 acquired 15,897,909 shares of Haier Biomedical, representing 5% of the total share capital, through secondary market transactions from August 14, 2024, to October 14, 2025 [4][6]. - The investment was made using self-owned funds, and there are no immediate plans to increase or decrease the stake in the next 12 months [6][8]. Group 2: Company Background - Haier Biomedical is a subsidiary of Haier Group's health ecosystem brand, Yingkang Yisheng, established in October 2005 and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in October 2019 [13]. - The company has faced a continuous decline in stock price over the past four years, with significant drops of 29.83%, 35.46%, 12%, and 6.38% in 2022, 2023, 2024, and 2025 respectively [12][14]. Group 3: Financial Performance - In the first half of 2025, Haier Biomedical reported revenue of 1.196 billion yuan, a year-on-year decrease of 2.27%, and a net profit attributable to shareholders of 143 million yuan, down 39.09% year-on-year [14]. - The company noted that its new industries are growing well, contributing to 47% of total revenue, with significant growth in overseas business, which saw a 30.17% increase year-on-year [14].

【导读】海尔生物被久实优选1号私募证券投资基金举牌 中国基金报记者 吴君 10月15日晚间，海尔生物发布公告称，在本次增持以后，青岛久实投资管理有限公司（以下 简称久实投资）旗下久实优选1号私募证券投资基金（以下简称久实优选1号）拥有权益的股 份数量及占公司总股本的比例为5%，达到举牌线。 值得注意的是，海尔生物股价已经连续调整4年左右。国资背景的久实投资此时出手举牌，公 司表示意在未来发展中实现协同共赢。 久实投资举牌海尔生物 海尔生物最新发布公告称，2025年10月15日，公司收到久实投资（代表"久实优选1号"）发 来的《简式权益变动报告书》，基于对公司未来发展前景的信心和对公司长期投资价值的认 可，久实优选1号于2024年8月14日至2025年10月14日通过二级市场集中竞价和大宗交易方 式增持公司股份1589.79万股，占公司总股本的5.00%。 | | 基金名称 基金备案编号 | 久实优选 1 号私募证券投资基金 SJD567 | | | | | --- | --- | --- | --- | --- | --- | | 信息披露 义务人基 本信息 | | | | | | | | 基金管理人名称 | ...

Core Insights - On October 15, Haier Biomedical and Hainan Huatie disclosed shareholding increases, while 23 A-share listed companies announced shareholding reductions [1][3] Group 1: Shareholding Increases - Haier Biomedical's major shareholder, Jiusiyouxuan No.1 Private Securities Investment Fund, has become a shareholder with over 5% stake [3] - Hainan Huatie's second-largest shareholder, Hu Danfeng, completed a share increase plan, accumulating 6.448 million shares [3] Group 2: Shareholding Reductions - Ugreen Technology plans to reduce its shareholding by up to 1.5% [3] - Dongxin Peace's directors, Chen Zongchao and Huang Xiaopeng, plan to reduce their shareholdings [3] - Meilixin's director, Ma Minghai, and others intend to reduce their holdings by up to 0.34% [3] - Dongsoft Zhaibo's controlling shareholder, Lanhai Ruisheng, plans to reduce its stake by up to 1.06% [3] - Demingli's second-largest shareholder, Wei Hongzhang, intends to reduce its holdings by up to 1.32% [3] - Nanling Technology's shareholders plan to collectively reduce their holdings by up to 3.26% [3] - Lio Co., Ltd. plans to reduce up to 135 million shares of its repurchased shares [3] - Huizhiwei's second-largest shareholder, the National Fund Phase II, plans to reduce its holdings by up to 1% [3] - Hahuan Huadong's shareholder, Hexie Investment, plans to reduce its holdings by up to 1% [3] - Huichuangda's shareholder, Ningbo Tongjia, plans to reduce its holdings by up to 2.9999% [3] - Jinsong New Materials' shareholder, Ningbo Liyi, plans to reduce its holdings by up to 2% of the total share capital [3] - Feirongda's controlling shareholder and actual controller plan to reduce their holdings [3] - Deyi Culture's specific shareholder, Chen Lan, plans to reduce its holdings by up to 1% [3] - Sanfeng Intelligent's Dong Chenwei and his associates plan to reduce their holdings by up to 2.85% [3] - Yilian Forging's shareholder, Gaoxin Tonghua, plans to reduce its holdings by up to 3% [3] - Huada Jiutian's fourth-largest shareholder, the National Fund, has cumulatively reduced 2.7147 million shares [3] - Riyue Co., Ltd.'s director and vice president, Zhang Jianzhong, plans to reduce up to 156,900 shares [3] - Western Gold's second-largest shareholder, Yang Niurong, plans to reduce up to 18.22 million shares [3] - Yonghui Supermarket's vice president, Luo Wenxia, plans to reduce up to 109,000 shares [3] - Baobian Electric's shareholder, the financial arm of the military industry, plans to reduce up to 0.98% [3] - Keli Sensor's Lu Zhonggeng and Huang Zhaoxia plan to reduce their holdings by up to 0.4807% and 0.0359% respectively [3] - Shuhua Sports' shareholders plan to collectively reduce their holdings by up to 3% [3] - Jintuo Co., Ltd.'s shareholders, Pan Zhu He and others, plan to reduce their holdings by up to 2.95% [3]

Core Insights - On October 15, several A-share listed companies disclosed their shareholding changes, with notable increases and decreases in holdings by major shareholders [1] Group 1: Increased Holdings - Haier Biomedical's major shareholder, Jiusiyouxuan No.1 Private Securities Investment Fund, has become a shareholder with over 5% stake [2] - Hainan Huate's second-largest shareholder, Hu Danfeng, completed a share buyback plan, accumulating 6.448 million shares [2] Group 2: Decreased Holdings - Ugreen Technology's shareholders plan to reduce their holdings by up to 1.5% [2] - Dongxin Peace's directors, Chen Zongchao and Huang Xiaopeng, are planning to sell shares [2] - Meilixin's director, Ma Minghai, and others intend to reduce their holdings by up to 0.34% [2] - Dongsoft Zhaibo's controlling shareholder, Lanhai Ruisheng, plans to reduce holdings by up to 1.06% [2] - Demingli's second-largest shareholder, Wei Hongzhang, intends to reduce holdings by up to 1.32% [2] - Nanling Technology's shareholders plan to collectively reduce holdings by up to 3.26% [2] - Liou Co. plans to reduce up to 135 million shares of repurchased stock [2] - Huizhiwei's second-largest shareholder, the National Fund II, plans to reduce holdings by up to 1% [2] - Other companies, including Hahai Transportation, Huichuangda, and others, have also announced plans for share reductions [2]

北京商报讯（记者 丁宁）10月15日晚间，海尔生物（688139）发布公告称，10月15日，公司收到青岛 久实投资管理有限公司（代表"久实优选1号私募证券投资基金"，以下简称"久实优选1号"）《青岛海尔 生物医疗股份有限公司简式权益变动报告书》，基于对公司未来发展前景的信心和对公司长期投资价值 的认可，久实优选1号于2024年8月14日至2025年10月14日通过二级市场集中竞价和大宗交易方式增持公 司股份1589.79万股，占公司总股本的5%。 公告显示，本次权益变动后，久实优选1号拥有权益的股份数量占海尔生物总股本的比例为5%。 ...

格隆汇10月15日丨海尔生物(688139.SH)公布,基于对公司未来发展前景的信心和对公司长期投资价值的认可,久实优选1号于2024年8月14日至2025年10月14日通过二级市场集中竞价和大宗 本次权益变动属增持，资金来源为久实优选 1 号自有资金，不触及要约收购。 ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-047 青岛海尔生物医疗股份有限公司 关于股东增持股份达到 5%的权益变动提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示 2 二、本次权益变动前后，信息披露义务人持有公司股份变动情况 名称 股份种类 本次权益变动前持有股 份情况 本次权益变动后持有 股份情况 久实优 选1号 股数（股） 占总 股本 比例 （%） 股数（股） 占总 股本 比例 （%） 人民币普通股 15,878,909 4.99 15,897,909 5.00 本次权益变动后青岛久实投资管理有限公司-久实优选 1 号私募证券投 资基金拥有权益的股份数量及占青岛海尔生物医疗股份有限公司（以下简称"海 尔生物"，"公司"）总股本的比例为 5%。 本次权益变动不会使公司控股股东、实际控制人发生变化。 一、本次权益变动基本情况 2025 年 10 月 15 日，公司收到青岛久实投资管理有限公司（代表"久实优 选 1 号私募证券投资基金"，以下简称"久实优选 1 号"或"信息披 ...

青岛海尔生物医疗股份有限公司 简式权益变动报告书 签署日期：2025年10月15日 上市公司名称： 青岛海尔生物医疗股份有限公司 股票上市地点： 上海证券交易所 股票简称： 海尔生物 股票代码： 688139.SH 信息披露义务人： 青岛久实投资管理有限公司（代表"久实优选1号私募 证券投资基金"） 基金备案编号 SJD567 住所： 青岛市市南区香港西路48号海天中心T2 通讯地址： 青岛市市南区香港西路48号海天中心T2 股份变动性质： 股份增加，成为5%以上股东 信息披露义务人声明 一、本信息披露义务人根据《中华人民共和国证券法》（以下简称"《证券 法》"）《上市公司收购管理办法》（以下简称"《收购办法》"）《公开发行证 券公司信息披露内容与格式准则第 15 号——权益变动报告书》（以下简称 "《准则 15 号》"）等相关的法律、法规及规范性文件编写本报告书。 二、信息披露义务人签署本报告已获得必要的授权和批准，其履行亦不违 反信息披露义务人内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》《准则 15 号》规定，本报告书已全面覆 盖信息披露义务人在青岛海尔生物医疗股份有限公司（以下简 ...